How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

192 results for

Vulvar Dermatitis

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Management of vulval conditions

C. ISSVD Terminology and Classification of Vulvar Dermatological Disorders: An Approach to clinical diagnosis. Presented at the XXI World Congress of the ISSVD, Paris, France Sept 3-8 2011 23.Nardelli A, Degreef H, Goossens A. Contact allergic reactions of the vulva: a 14 year review. Dermatitis 2004;15:131-6 24.Haverhoek E, Reid C, Gordon L et al Prospective study of patch testing in patients with vulval pruritis. Australas J Dermatol. 2008;49(2):80-5 25.Lotti T, Buggiani G, Prignano F. Prurigo (...) nodularis and lichen simplex chronicus. Dermatol Ther 2008; 21:42-46. 26.Lynch PJ. Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region. Dermatol Ther 2004; 17: 8-19 27.Crone AM, Stewart EJ, Wojnarowska F, Powell SM. Aetiological factors in vulvar dermatitis. J Eur Acad Dermatol Venereol 2000;14:181-6. 28.Meeuwis KA, et al. Genital psoriasis: A systematic literature review on this hidden skin disease. Acta Derm Venereol. 2011 Jan; 91(1):5-11. 29.Hording U, Daugaard S, Iversen AK et

2014 British Association for Sexual Health and HIV

42. Management of molluscum contagiosum

), especially in the setting of immuno- compromise. 14,21,22 Other uncommon manifestations include cystic, cellulitis, or abscess-like lesions, 14,23–27 cutaneous pseudolymphomas, 28–31 folliculitis 32,33 or warty appearances. 34 Commonly, patients have 1–30 individual lesions at a time, 35 occurring as clusters, and these can become koebnerised. Especially lesions in later stages, at point of regression, can be surrounded by an in?ammatory dermatitis. 36,37 Molluscum infection can a?ect almost any part (...) /Vol00000/140182/APPFile/SG-STDJ140182.3d (STD) [PREPRINTER stage] abscesses,keratoacanthomaandcutaneoushorn.Genital molluscum may also be confused with ectopic sebaceous glands 93,94 and vulvar lymphangioma circumscrip- tum. 95,96 Patientsmayconfusegenitallesionswithgenital warts. Themostsigni?cantdi?erentialdiagnosesofmollus- cum however are the cutaneous manifestations of disseminated fungal infections, usually presenting in late immunosuppression, including Penicilliosis, 97–99 Cryptococcosis, 100

2014 British Association for Sexual Health and HIV

43. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society

neuronsinthevagina.Thisfunctionmayservetodecreasethe discomfort associated with VVA. 11 The term vulvovaginal atrophy refers specifically to the changes in the vaginal and vulvar surfaces that on examina- tion arethin,pale,anddry.Thevaginacannarrowandshorten, and the introitus may constrict, especially in the absence of penetrative sexual activity. The vaginal lining may exhibit petechiae and become thinner (often only a few cell layers thick),lesselastic,andprogressivelysmootherasrugalfolds decrease. Vaginal blood flow diminishes. Although (...) ability to have pain-free sexual activity. 33<36 Dyspareunia has been shown to be strongly associated with female sexual dysfunction in postmeno- pausal women. 31 Decreased genital arousal and vulvar pain disorders may occur as a consequence of VVA. Atrophy and phimosis of the prepuce of the clitoris may result in dyspareuniathatleads todecreasedinterestinandavoidance of sexual activity. 37 In these scenarios, dyspareunia or avoid- ance of sexual activity may be a presentation of VVA. Vulvar

2013 The North American Menopause Society

44. ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

Detailed Description: This study is intended to explore clinical efficacy and safety/tolerability of ICVT as a potential treatment for benign and premalignant HPV-induced genital lesions in immunocompetent and immunosuppressed patients. This includes 3 different patient populations: i) immunocompetent patients with anogenital warts (AGWs), ii) immunocompromised patients with anogenital warts and iii) immunocompromised patients with vulvar high grade squamous intraepithelial neoplasia (HSIL), formerly (...) referred to as usual type vulvar intraepithelial neoplasia (uVIN). Since digoxin / furosemide ICVT's mode of action is in part independent of the immune system and directly targeted to eradicate the causative HPV, we hypothesize this therapy to be of value in this specific group of individuals. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 28 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention

2017 Clinical Trials

45. Labial fusion: A rare cause of urinary retention in reproductive age woman and review of literature Full Text available with Trip Pro

Labial fusion: A rare cause of urinary retention in reproductive age woman and review of literature Labial fusion usually affects prepubertal girls and postmenopausal women, it may rarely occurs in reproductive years in the absence of predisposing factors such as vulvar infections, dermatitis, trauma, female circumcision and lichen sclerosis. Should be considered in differential diagnosis in the differential diagnosis of urinary retention even if the patient doesn't have history of sexual

2017 Turkish journal of urology

46. Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema

with presented subacute eczema from early on-set. Subacute eczema usually presents with papule, excoriations, crusting and pruritus. Occasionally patient will present with papulovesicle, blister and erosion. Patients also need to meet the requirement of: Subjects must have body surface area (BSA) disease involvement between 3-10% (inclusive) as assessed by palm method; IGA score of 2 or 3; Skin lesions should be on the trunk or extremities, without palms/soles, face/scalp, and vulvar areas involved; Based (...) : April 28, 2017 Last Update Posted: January 24, 2019 Last Verified: January 2019 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Zai Lab Pty. Ltd.: subacute Additional relevant MeSH terms: Layout table for MeSH terms Eczema Dermatitis Skin Diseases Skin Diseases, Eczematous

2017 Clinical Trials

47. Lichen sclerosus in women: a review. (Abstract)

Lichen sclerosus in women: a review. Female lichen sclerosus is a chronic inflammatory dermatitis, with a predilection for the anogenital area, which in some cases can become seriously distorted (atrophy of the labia minora, phimosis, introital stenosis, etc.). Most cases are diagnosed in postmenopausal women, but it can affect women of any age. Lichen sclerosus is usually a pruriginous condition, although it can also be asymptomatic. It is associated with an increased risk of vulvar cancer (...) , even though it is not a premalignant condition itself. The true precursor of cancer associated with lichen sclerosus is vulvar intraepithelial neoplasia, differentiated type. The diagnosis is usually clinical, but in some cases a biopsy can be performed, especially to exclude vulvar intraepithelial neoplasia or cancer. The treatment of lichen sclerosus aims at controlling the symptoms, stopping further scarring and distortion and reducing the risk of cancer. The gold standard in treatment is ultra

2017 Climacteric

48. Topical Corticosteroid

(Level 4-5) (vulvar) Nummular Perianal inflammation (severe cases) (only after the anti- agent has been used) Severe Low potency s (Level 6-7) Dermatitis (face, s, diaper area) Perianal inflammation References XIII. Dosing: Corticosteroid Potency Selection by distribution Low potency Topical Corticosteroids Face Groin Intertriginous areas Mid-potency Topical Corticosteroids Thin skin trunk areas Extremity lesions High potency Topical Corticosteroids Thick skin trunk areas Extremity lesions Very high (...) absorption with systemic steroid effects Skin atrophy Rebound papular dermatitis after medium-high potency Avoid high potency steroid on genital or face Striae formation Telangiectasia IV. Example: Lower cost, generic steroids Level 1: Clobetasol Propionate 0.05% ointment (price jump to $200 for 45 g in 2017) Level 2: Betamethasone Dipropionate 0.05% ointment Level 3: Betamethasone Dipropionate 0.05% cream Level 4: Triamcinolone Acetonide 0.1% ointment Level 5: Triamcinolone Acetonide 0.1% ointment Level

2018 FP Notebook

49. Vulvodynia

Vulvodynia Vulvodynia Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Vulvodynia Vulvodynia Aka: Vulvodynia , Vulvar Pain (...) , Dysesthetic Vulvodynia , Essential Vulvodynia , Vulvar Dysesthesia From Related Chapters II. Definitions Vulvodynia Chronic vulvar discomfort is stinging, burning, and raw No visible dermatoses No identifiable neurologic disorder Erythema may be only finding III. Types Spectrum of Vulvodynia Previously known as Timing Provoked Vulvodynia (triggered by touch) Unprovoked Vulvodynia (continuous Vulvodynia) IV. Symptoms Characteristics Burning, irritating, or sharp pain Timing: Onset with provocation, lasting

2018 FP Notebook

50. Lichen Simplex Chronicus

Simplex Chronicus Aka: Lichen Simplex Chronicus , Lichen Simplex , Circumscribed Neurodermatitis , Lichen Simplex Nuchae , Scalp Picker's Nodule , Vulvar Lichen Simplex Chronicus , Red Scrotum Syndrome From Related Chapters II. Pathophysiology Lichenified skin reaction to chronic scratching (may occur while asleep) III. Causes s (most common) , or Skin cancers Exacerbating factors Heat or excessive sweating Irritation from overlying clothing Topical cleansers, lotions or other products IV. Signs (...) the itch-scratch cycle See s for specific locations Triamcinolone 0.1% ointment twice daily until active dermatitis resolves Advance to Clobetasol 0.05% daily if refractory after 2-3 weeks Consider oral s if still refractory after 2-3 weeks Intertriginous areas (perianal area or behind ear) Triamcinolone 0.1% ointment twice daily until active dermatitis resolves Scalp gel applied twice daily until active lesions resolve Inject intralesional ( 10 mg/ml) for scalp s Consider 20 mg twice daily for 2 weeks

2018 FP Notebook

51. Subtypes of Provoked Vestibulodynia

Inclusion Criteria: A history of 3 months or more of vulvar pain suggestive of PVD, i.e. symptoms of pain on vaginal penetration (insertional dyspareunia and/or pain with tampon insertion). On exam, tenderness localized within the vestibule when being touched with a cotton-tip applicator. No identifiable cause for the pain, such as vulvovaginal candidiasis, vaginal atrophy, desquamative inflammatory vaginitis (DIV), herpes, dermatitis or vulvar dystrophy. Exclusion criteria: other causes for vulvar pain (...) recruitment to 3 months, 6 months 6 months, 9 months and 12 months ] The exam is performed by touching the vestibule with a cotton-tip applicator in 6 defined points (2,5,6,7, 10 and 12),while the patient is being asked to rate the intensity of pain verbally from 0 to 10 at each point. Secondary Outcome Measures : Visual analog scale (VAS) [ Time Frame: Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months ] Measurement of vestibular tenderness using a vulvar algesiometer [ Time Frame

2016 Clinical Trials

52. TOL-463 Phase 2 Study for Vaginitis

, or contact dermatitis involving the vulvar epithelium. Presence of T. vaginalis on wet mount or evidence of other infectious cause of cervicitis or vaginitis on physical examination. Active genital lesions, including ulcers, vesicles consistent with herpes, or warts. Use of metronidazole or other 5-nitro-imidazole derivative or clindamycin or an antifungal agent (intravaginal or systemic) for the treatment of any condition within 14 days of start of study. Planned ongoing immunosuppressive therapy (...) the course of the trial. e.g., antifungal preparations, deodorant sprays, spermicides, contraceptive creams, gels, foams, sponges Participant is willing to refrain from using tampons and diaphragms for the seven days of the study product use. Exclusion Criteria: A diagnosis of vaginitis other than BV or VVC or another vaginal or vulvar condition* that might confuse interpretation of response to study product. Examples of such conditions include erosive lichen planus, desquamative interstitial vaginitis

2016 Clinical Trials

53. The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia

Inclusion Criteria: A history of 3 months or more of vulvar pain suggestive of PVD, i.e. symptoms of pain on vaginal penetration (insertional dyspareunia and/or pain with tampon insertion). On exam, tenderness localized within the vestibule when being touched with a cotton-tip applicator. No identifiable cause for the pain, such as vulvovaginal candidiasis, vaginal atrophy, desquamative inflammatory vaginitis (DIV), herpes, dermatitis or vulvar dystrophy. Exclusion Criteria: other causes for vulvar pain (...) by touching the vestibule with a cotton-tip applicator in 6 defined points (2,5,6,7, 10 and 12),while the patient is being asked to rate the intensity of pain verbally from 0 to 10 at each point. Secondary Outcome Measures : Measurement of vestibular tenderness using a vulvar algesiometer [ Time Frame: Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months. ] Change of pain using Visual analog scale [ Time Frame: Change in VAS between recruitment to 3 months, 6 months , 9 months and 12

2016 Clinical Trials

54. Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis

of an alternative or specific treatment. Not considered as "Treatment Failure": The need to initiate a specific treatment because of a Sexually Transmitted Infection (STI) (trichomoniasis; gonococcal and chlamydial infections) detected from the vaginal sample at Visit 1 / D1. Patients presenting with only vulvar complaints not considered as related to infectious vaginitis. Secondary Outcome Measures : Change in Vaginal Discharge and in Each Associated Vaginal Clinical Symptoms Reported by the Patient (...) . suprainfected fungal vaginitis) and able to receive an empirical local treatment Exclusion Criteria: Recurrent patient; i.e. a patient who has had at least 4 episodes of infectious vaginitis in the 12 months prior to inclusion Vaginal infection justifying systemic therapy History of atrophic vaginitis or suspected atrophic vaginitis at inclusion Patient presenting with signs of genital herpes or signs of non-infectious vulvar pathology (vulvodynia, psoriasis, eczema, lichen sclerosus, lichen planus, contact

2015 Clinical Trials

55. Profiling Vulvodynia Based on Neurobiological and Behavioral Endophenotypes

Sample Study Population Women 18-55 yo with vestibulodynia, and or generalized vulvodynia, characterized by at least 3 months history of pain, burning, or irritation, with an intensity of 4/10 or greater, of the vulva localized to the vestibule (vestibulodynia) with or without pain located in outer region of the vulva (generalized VD). The pain must NOT be attributable to current bacterial, fungal, or yeast infections, a skin condition (eg; dermatitis), hormonal changes, or vaginitis. Criteria (...) , with an intensity of 4/10 or greater of the vulva either localized to the vestibule and precipitated by contact of the vestibule (Provoked VD) or located in other regions of the vulva (called GVD). The pain must not be attributable to dermatitis, dermatosis, candida, hormonal changes, or vaginitis. Generally healthy without current neurological, cardiovascular, hepatic, renal, autoimmune diseases, diabetes or cancer. Willingness to use acceptable contraceptive methods (e.g., hormonal, barrier, or sterilization

2015 Clinical Trials

56. Clobetasol Proprionate Versus Fractionated CO2 Laser for the Treatment of Lichen Sclerosus

Measures : SkinDEX-29 Score [ Time Frame: Change from baseline score to score at six months ] Validated subjective measure of vulvar symptoms of itching, burning, dyspareunia of Lichen Sclerosus, described as a total numeric score Secondary Outcome Measures : Number of patients with adverse outcomes [ Time Frame: One year from treatment ] Total number with adverse outcomes to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment Number (...) Posted : October 12, 2015 Last Update Posted : August 17, 2018 See Sponsor: Medstar Health Research Institute Information provided by (Responsible Party): Medstar Health Research Institute Study Details Study Description Go to Brief Summary: This study is being done to compare the effects, good and bad, of fractionated CO2 laser treatment and clobetasol proprionate .05% ointment on vulvar lichen sclerosus. Condition or disease Intervention/treatment Phase Vulvar Lichen Sclerosus Device: Fractionated

2015 Clinical Trials

57. Smoking Cessation Strategies in Community Cancer Programs for Lung and Head and Neck Cancer Patients

Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients must be ≥ 18 years of age. Patient with newly diagnosed or recurrent, histologic diagnosis of any of the following tobacco related malignancies: Lung or Bronchus cancer or Head & Neck, cancers (all sites). Esophagus, Stomach, Pancreas, Kidney, Urinary Bladder, Colon, Rectum, Cervix, Vulvar, Vaginal Carcinoma in situ undergoing definitive surgical (...) of Bipolar disorder. Currently taking Bupropion for depression. Patient has taken monoamine oxidase inhibitors (MAOI) in the past two weeks. History of eating disorder such as anorexia or bulimia. Active widespread skin disorders such as psoriasis, chronic urticarial or dermatitis History of epilepsy or seizure disorder. Active severe kidney or liver disease. Women must not be pregnant or lactating. Women of reproductive-potential must have negative serum or urine pregnancy test within 7 days prior

2014 Clinical Trials

58. Treatment of Prepubertal Labial Adhesions

for eligibility information Ages Eligible for Study: 3 Months to 12 Years (Child) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Prepubertal girls ages 3 months to 12 years with labial adhesions Exclusion Criteria: Presence of underlying dermatologic conditions such as lichen sclerosis, severe atopic dermatitis, psoriasis or vitiligo Presence of systemic conditions that can have vulvar manifestations such as Crohn's disease and Behçet disease Presence of disorders (...) with topical estrogen with lateral traction as compared to an emollient with lateral traction. Condition or disease Intervention/treatment Phase Prepubertal Labial Adhesions Drug: Estradiol cream 0.01% Drug: Cetaphil Not Applicable Detailed Description: The etiology of labial adhesions is unclear but appears to be related to hypoestrogenism in combination with vulvar irritation. For many years, first-line treatment for labial adhesions in prepubertal girls has been topical estrogen. With the use of topical

2014 Clinical Trials

59. VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness

, vulvar vestibulitis dysethetic vulvodynia or vulvar dystrophy, current/chronic papulosquamous vulvar dermatoses (e.g., psoriasis lichen planus, tinea cruris, lichen sclerosis, seborrhea dermatitis, contact or irritant dermatitis, lichen simplex, eczema) or bullous dermatoses or systemic diseases with potential involvement of vulva) Has Irritable Bowel Syndrome or Crohn's Disease Has dyspareunia defined as recurrent or persistent painful intercourse that affects sexual activity Has been in another (...) , radiation therapy, or pelvic floor physical therapy Has an implantable pacemaker, an automatic implantable cardioverter/defibrillator (AICD), or any other implantable electrical device, as these devices may be adversely affected by radiofrequency fields or current Has undergone the Viveve Procedure previously Has medical condition that in investigator's opinion may interfere with wound healing response Has an acute or a chronic vaginal or vulvar disorder (e.g., vaginal atrophy, pain including vulvodynia

2014 Clinical Trials

60. Vulvovaginitis (Follow-up)

: Jill M Krapf, MD, FACOG; Chief Editor: Christine Isaacs, MD Share Email Print Feedback Close Sections Sections Vulvovaginitis Overview Practice Essentials Vulvovaginitis is a general term referring to many types of vaginal infection, although this article focuses on the following disorders, which affect the vulvar region: Vulvovaginal candidiasis Atrophic vaginitis Vulvar vestibulitis Contact dermatitis Signs and symptoms Acute vulvovaginal candidiasis Vulvar pruritus and burning - Primary symptoms (...) , and a feeling of rawness that is aggravated by stress, exercise, tight clothing, coitus, and tampon use. The pain is usually not considered constant but is elicited by any attempt to enter the vagina. Other symptoms may include the following: Irritating vaginal discharge Vulvar burning sensation Small spots of erythema around the vestibular glands, with rare ulceration Contact dermatitis Pruritus is the cardinal symptom. However, an acute reaction may develop as a result of exposure to a potent irritant


To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>